Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Short Interest Down 5.6% in April

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 3,520,000 shares, a drop of 5.6% from the March 31st total of 3,730,000 shares. Currently, 3.9% of the shares of the company are sold short. Based on an average daily volume of 566,600 shares, the short-interest ratio is presently 6.2 days.

Acadia Healthcare Trading Up 1.4 %

Shares of NASDAQ:ACHC opened at $74.61 on Tuesday. The firm has a fifty day moving average of $77.91 and a two-hundred day moving average of $77.73. The firm has a market capitalization of $6.90 billion, a P/E ratio of -298.43, a price-to-earnings-growth ratio of 2.17 and a beta of 1.31. Acadia Healthcare has a 12-month low of $66.49 and a 12-month high of $87.77. The company has a quick ratio of 0.67, a current ratio of 0.67 and a debt-to-equity ratio of 0.48.

Acadia Healthcare (NASDAQ:ACHC) last released its quarterly earnings results on Wednesday, February 28th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.80 by $0.05. The business had revenue of $742.80 million for the quarter, compared to the consensus estimate of $727.60 million. Acadia Healthcare had a negative net margin of 0.74% and a positive return on equity of 11.21%. Acadia Healthcare’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.70 EPS. On average, equities analysts expect that Acadia Healthcare will post 3.57 EPS for the current fiscal year.

Insider Activity at Acadia Healthcare

In other news, Director Wade D. Miquelon sold 2,203 shares of Acadia Healthcare stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $85.39, for a total transaction of $188,114.17. Following the completion of the sale, the director now directly owns 46,074 shares in the company, valued at approximately $3,934,258.86. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Campbell & CO Investment Adviser LLC boosted its position in shares of Acadia Healthcare by 177.4% during the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 7,357 shares of the company’s stock valued at $517,000 after acquiring an additional 4,705 shares in the last quarter. Vaughan Nelson Investment Management L.P. bought a new position in shares of Acadia Healthcare in the fourth quarter worth about $24,157,000. Louisiana State Employees Retirement System bought a new position in shares of Acadia Healthcare in the fourth quarter worth about $2,014,000. Phocas Financial Corp. bought a new stake in shares of Acadia Healthcare during the fourth quarter worth approximately $6,887,000. Finally, Jennison Associates LLC raised its stake in shares of Acadia Healthcare by 26.1% during the fourth quarter. Jennison Associates LLC now owns 1,148,755 shares of the company’s stock worth $89,327,000 after buying an additional 238,114 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have commented on the stock. Deutsche Bank Aktiengesellschaft raised shares of Acadia Healthcare from a “sell” rating to a “hold” rating and set a $70.00 target price for the company in a research note on Thursday, April 25th. Stephens raised shares of Acadia Healthcare from an “equal weight” rating to an “overweight” rating and set a $92.00 price objective for the company in a research note on Friday, January 5th. Barclays began coverage on shares of Acadia Healthcare in a research report on Wednesday, March 6th. They set an “overweight” rating and a $100.00 price target for the company. TheStreet upgraded shares of Acadia Healthcare from a “c” rating to a “b-” rating in a research note on Monday, March 4th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $94.00 target price on shares of Acadia Healthcare in a research note on Monday, March 4th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Acadia Healthcare presently has a consensus rating of “Moderate Buy” and an average target price of $92.00.

About Acadia Healthcare

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.